Licensing

Our specialist healthcare team, with backgrounds in the life sciences, understand the complexities of valuations and deal structures that are unique to licensing deals in pharma and biotech and are with our clients every step of the way.

We support clients with:

- In-licensing
- Out-licensing
- Drug licensing
- Facility licensing

Our Latest Deals

May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monocloncal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Feb 2022
has received investment from
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has received investment from
Nov 2021
has made an investment in
company name confidential
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
a Sovereign Capital Partners-backed company
has acquired

Results. Great people creating great outcomes, together.

Latest Insights

Insights
24th May 2022

Crossrail opens – a big day for travellers to and workers in London

At Results Healthcare we execute transactions around the world, with active projects in North America, Europe and Asia Pacific, so we see ourselves as a global organisation with offices and employees in London and New York, so a blog on transport in London might seem oddly parochial, but the opening of Crossrail, or the Elizabeth […]

Reports
4th May 2022

The Technology Services Perspective – Q1 2022

Deal activity for Q1 2022 has increased 30% over the previous quarter, to a total of 237 transactions. Transactions have mainly focused on strategic tuck-ins that are centred around acquiring next-gen and nearshore capabilities, such as robotic process automation, customer experience consultancy and influencer-based social media marketing. Even in the current macro environment, March showed […]

Reports
4th May 2022

The CyberScope – Q1 2022

Despite a backdrop of some macroeconomic uncertainty, the first quarter of 2022 started strong with 52 M&A transactions, representing a 41% increase from Q1 last year, as the security sector again proves its strong resilience. Google’s $5.4Bn acquisition of cloud and managed cybersecurity provider, Mandiant, very clearly demonstrated the opening of a new front in […]